| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
(-)-GSK598809 hydrochloride selectively targets the dopamine D3 receptor (DRD3). It acts as a potent antagonist at this receptor, with reported IC50 values of 1.1 nM for the dopamine D2 receptor, indicating high affinity for the D3 receptor as well.
|
|---|---|
| ln Vitro |
As a selective DRD3 antagonist, (-)-GSK598809 hydrochloride exhibits high affinity binding to the dopamine D3 receptor in vitro. It has been shown to selectively enhance reward anticipation in drug and alcohol dependence during monetary incentive delay tasks, suggesting its ability to modulate dopaminergic signaling in reward-related brain regions.
|
| ln Vivo |
In vivo, (-)-GSK598809 has been investigated for its effects on reward processing and substance dependence. It may repair reward deficits in substance dependence by modulating dopamine D3 receptor-mediated signaling. The compound has shown potential in preclinical models for studying the neurobiological basis of addiction and related psychiatric disorders.
|
| Enzyme Assay |
The binding affinity of (-)-GSK598809 hydrochloride to dopamine D3 receptors is typically assessed using radioligand binding assays. Membranes from cells expressing recombinant human dopamine D3 receptors are incubated with a radiolabeled antagonist (e.g., [³H]-spiperone) in the presence of varying concentrations of the test compound. Nonspecific binding is determined using a competing ligand. IC50 values are calculated from competition binding curves.
|
| Cell Assay |
In vitro cellular assays for (-)-GSK598809 hydrochloride typically involve cell lines engineered to express human dopamine D3 receptors coupled to a signaling pathway such as cAMP inhibition. Cells are pre-incubated with the compound, then stimulated with a D3 receptor agonist (e.g., dopamine or quinpirole). The extent of receptor activation is measured by quantifying cAMP levels using ELISA or HTRF-based detection methods.
|
| Animal Protocol |
In vivo animal studies with (-)-GSK598809 hydrochloride typically involve rodent models of reward and addiction. The compound is administered via intraperitoneal (i.p.) or oral (p.o.) routes. Behavioral assays such as conditioned place preference (CPP), self-administration, or intracranial self-stimulation (ICSS) are used to assess the compound's effects on reward processing and motivation.
|
| ADME/Pharmacokinetics |
Dopamine D3 receptor antagonists such as (-)-GSK598809 hydrochloride generally exhibit favorable oral bioavailability and blood-brain barrier penetration. The compound is typically formulated in suitable vehicles (e.g., saline, DMSO, or PEG-based solutions) for in vivo administration. Pharmacokinetic parameters such as half-life (t₁/₂), maximum concentration (Cmax), and area under the curve (AUC) are determined from plasma samples following administration.
|
| Toxicity/Toxicokinetics |
The compound is provided for research use only and is not approved for human therapeutic use. Standard preclinical toxicity assessments would include evaluation of acute toxicity in rodents, as well as safety pharmacology studies to assess effects on cardiovascular, respiratory, and central nervous system function. No specific toxicity data is available in the public domain for this compound.
|
| References |
Elrashidi MY, Ebbert JO. Emerging drugs for the treatment of tobacco dependence: 2014 update. Expert Opin Emerg Drugs. 2014 Jun;19(2):243-60. doi: 10.1517/14728214.2014.899580. Epub 2014 Mar 22. PMID: 24654737.
|
| Additional Infomation |
(-)-GSK598809 hydrochloride is a research-grade chemical used exclusively for laboratory investigations. As a selective dopamine D3 receptor antagonist, it serves as a valuable pharmacological tool for studying the role of D3 receptors in neuropsychiatric disorders including addiction, schizophrenia, and Parkinson's disease. The compound has not advanced to clinical trials for therapeutic use.
|
| Molecular Formula |
C22H24CLF4N5OS
|
|---|---|
| Molecular Weight |
517.970476150513
|
| Exact Mass |
517.13
|
| Elemental Analysis |
C, 51.01; H, 4.67; Cl, 6.84; F, 14.67; N, 13.52; O, 3.09; S, 6.19
|
| CAS # |
863766-31-8
|
| Related CAS # |
863680-45-9; (-)-GSK598809 hydrochloride;863766-31-8; 863680-46-0; 1310803-30-5; 1008521-08-1 (tartrate); 1008521-09-2 (tartrate hydrate)
|
| PubChem CID |
67021274
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
34
|
| Complexity |
704
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3C[C@@H]4C[C@@]4(C3)C5=C(C=C(C=C5)C(F)(F)F)F.Cl
|
| InChi Key |
XHSASHVDEMJIMD-NVJCMEIXSA-N
|
| InChi Code |
InChI=1S/C22H23F4N5OS.ClH/c1-13-18(32-12-27-13)19-28-29-20(30(19)2)33-7-3-6-31-10-15-9-21(15,11-31)16-5-4-14(8-17(16)23)22(24,25)26;/h4-5,8,12,15H,3,6-7,9-11H2,1-2H3;1H/t15-,21-;/m0./s1
|
| Chemical Name |
5-(5-((3-((1S,5R)-1-(2-fluoro-4-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexan-3-yl)propyl)thio)-4-methyl-4H-1,2,4-triazol-3-yl)-4-methyloxazole hydrochloride
|
| Synonyms |
(-)-GSK598809 hydrochloride; (-)-GSK-598809 hydrochloride; (-)-GSK-598809 HCl; (1S,5R)-GSK598809 hydrochloride; SCHEMBL1407735;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~241.33 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9306 mL | 9.6531 mL | 19.3061 mL | |
| 5 mM | 0.3861 mL | 1.9306 mL | 3.8612 mL | |
| 10 mM | 0.1931 mL | 0.9653 mL | 1.9306 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
